These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25003351)

  • 1. Endocrine therapy for advanced breast cancer.
    Shah PD; Dickler MN
    Clin Adv Hematol Oncol; 2014 Apr; 12(4):214-23. PubMed ID: 25003351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.
    Scott SM; Brown M; Come SE
    Expert Opin Drug Saf; 2011 Sep; 10(5):819-26. PubMed ID: 21699443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
    Gradishar W
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
    Bartsch R; Bago-Horvath Z; Berghoff A; DeVries C; Pluschnig U; Dubsky P; Rudas M; Mader RM; Rottenfusser A; Fitzal F; Gnant M; Zielinski CC; Steger GG
    Eur J Cancer; 2012 Sep; 48(13):1932-8. PubMed ID: 22459763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer.
    Arpino G; De Angelis C; Giuliano M; Giordano A; Falato C; De Laurentiis M; De Placido S
    Oncology; 2009; 77 Suppl 1():23-37. PubMed ID: 20130429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.
    Pan K; Chlebowski RT
    Clin Breast Cancer; 2014 Jun; 14(3):147-53. PubMed ID: 24503025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine therapy of advanced disease: analysis and implications of the existing data.
    Pritchard KI
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):460S-7S. PubMed ID: 12538501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD; Wood ME; Muss HB
    Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
    Oakman C; Moretti E; Santarpia L; Di Leo A
    Future Oncol; 2011 Feb; 7(2):173-86. PubMed ID: 21345137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
    Montagna E; Cancello G; Colleoni M
    Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
    Vergote I; Robertson JF
    Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulvestrant antiestrogen for treatment of breast cancer.
    Hancock CM
    Clin J Oncol Nurs; 2003; 7(2):201-2. PubMed ID: 12696217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
    Harichand-Herdt S; Zelnak A; O'Regan R
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):187-98. PubMed ID: 19192957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
    Prat A; Baselga J
    Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer.
    Montemurro F; Rossi V; Geuna E; Valabrega G; Martinello R; Milani A; Aglietta M
    Expert Opin Pharmacother; 2012 Oct; 13(15):2143-56. PubMed ID: 22984936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
    Cheung KL; Owers R; Robertson JF
    Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant ('Faslodex'): current and future role in breast cancer management.
    Howell A
    Crit Rev Oncol Hematol; 2006 Mar; 57(3):265-73. PubMed ID: 16473018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study.
    Neven P; Paridaens R; Pelgrims G; Martens M; Bols A; Goeminne JC; Vindevoghel A; Demol J; Stragier B; De Greve J; Fontaine C; Van Den Weyngaert D; Becquart D; Borms M; Cocquyt V; Van Den Broecke R; Selleslags J; Awada A; Dirix L; Van Dam P; Azerad MA; Vandenhoven G; Christiaens MR; Vergote I
    Breast Cancer Res Treat; 2008 May; 109(1):59-65. PubMed ID: 17592772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.